云南高校图书馆联盟文献共享服务平台- INHIBITORS

INHIBITORS: 作品数：1279被引量：2687H指数：18; 导出分析报告; 相关领域：医药卫生更多>>; 相关作者：张志丽刘俊义徐萍田超邹晓民更多>>; 相关机构：北京大学中国医学科学院北京协和医学院北京化工大学中国科学院更多>>; 相关期刊：更多>>; 相关基金：国家自然科学基金国家重点基础研究发展计划中国博士后科学基金国家教育部博士点基金更多>>

ALK inhibitors in cancer:mechanisms of resistance and therapeutic management strategies: 《Cancer Drug Resistance》2024年第1期690-711,共22页Darin Poei Sana Ali Shirley Ye Robert Hsu; Anaplastic lymphoma kinase(ALK)gene rearrangements have been identified as potent oncogenic drivers in several malignancies,including non-small cell lung cancer(NSCLC).The discovery of ALK inhibition using a tyrosine ...; 关键词：NSCLC ALK TKI acquired resistance alectinib CRIZOTINIB lorlatinib ceritinib brigatinib

The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer: 《Cancer Drug Resistance》2024年第1期644-660,共17页Bertha Alejandra Martinez-Cannon Ilaria Colombo; The introduction of immune checkpoint inhibitors(ICIs)has revolutionized the treatment landscape for numerous tumor types,including cervical and endometrial cancers.Multiple ICIs against programmed cell death-1(PD-1),...; 关键词：IMMUNOTHERAPY cervical cancer endometrial cancer immune checkpoint inhibitors

Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma: 《Cancer Drug Resistance》2024年第1期249-272,共24页Anum Jalil Melissa M Donate Jane Mattei; Melanoma is the most aggressive form of skin cancer,characterized by a poor prognosis,and its incidence has risen rapidly over the past 30 years.Recent therapies,notably immunotherapy and targeted therapy,have signifi...; 关键词：IMMUNOTHERAPY BRAF RESISTANCE MELANOMA overcoming resistance

Current applications of tumor local ablation(TLA)combined with immune checkpoint inhibitors in breast cancer treatment: 《Cancer Drug Resistance》2024年第1期439-458,共20页Lingpeng Tang Dandan Wang Ting Hu Xiaoying Lin Songsong Wu; supported by the Fujian Science and Technology Innovation Joint Funding Program(No.2023Y9332).; Breast cancer is one of the most common cancers in women globally,posing significant challenges to treatment because of the diverse and complex pathological and molecular subtypes.The emergence of immune checkpoint in...; 关键词：Tumor microenvironment antitumor immune response ablation immune checkpoint inhibitors

Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies被引量：1: 《Cancer Drug Resistance》2023年第4期768-787,共20页Rachel SJ Wong Rebecca JM Ong Joline SJ Lim; JSJ Lim is supported by the NMRC(NMRC/MOH/00414).All other authors have no funding to declare.; The use of immune checkpoint inhibitors(iCls)has increased exponentially in the past decade,although its progress specifically for breast cancer has been modest.The first U.S.Food and Drug Administration approval for ...; 关键词：IMMUNOTHERAPY immune checkpoint inhibitors resistance mechanisms breast cancer

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma被引量：3: 《Cancer Drug Resistance》2023年第4期858-873,共16页Patrick L.Sweeney Yash Suri Arnab Basu Vadim S.Koshkin Arpita Desai; Renal cell carcinoma(RCC),the most prevalent type of kidney cancer,is a significant cause of cancer morbidity and mortality worldwide.Antiangiogenic tyrosine kinase inhibitors(TKls),in combination with immune checkpoi...; 关键词：Antiangiogenic tyrosine kinase inhibitors renal cell carcinoma acquired resistance SUNITINIB tumor microenvironment immune checkpoint inhibitors

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia被引量：1: 《Cancer Drug Resistance》2023年第3期674-687,共14页Lindsay Gurska Kira Gritsman; supported by the National Institutes of Health(NIH)Grants R01CA196973(Gritsman K)and F31CA247172(Gurska L).; Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy that is associated with a high relapse rate and poor prognosis. Despite advances in immunotherapies in solid tumors and other hemat...; 关键词：Acute myeloid leukemia T cells immune checkpoint immune evasion

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma被引量：3: 《Cancer Drug Resistance》2023年第3期517-546,共30页Serena Astore Giulia Baciarello Linda Cerbone Fabio Calabrò; The introduction of first-line combinations had improved the outcomes for metastatic renal cell carcinoma (mRCC) compared to sunitinib. However, some patients either have inherent resistance or develop resistance as a...; 关键词：Renal cell carcinoma RESISTANCE tumor microenvironment checkpoint inhibitors target therapy

Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena: 《Cancer Drug Resistance》2023年第3期642-655,共14页Arya Mariam Roy Saby George; The introduction of immune checkpoint inhibitor (ICI) has revolutionized the treatment of metastatic renal cell carcinoma (mRCC) and has dramatically improved the outcomes of patients. The use of monotherapy or combin...; 关键词：Renal cell carcinoma immunotherapy immune checkpoint inhibitors primary resistance acquired resistance immune exhaustion markers immunosuppressive tumor microenvironment

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma: 《Cancer Drug Resistance》2023年第2期327-331,共5页Liia Akhuba Zhanna Tigai Dmitrii Shek; In 2030,pancreatic ductal adenocarcinoma(PDAC)will become the second leading cause of cancer-related mortality in the world.Unfortunately,neither conventional chemotherapy nor novel immunotherapeutic strategies can pr...; 关键词：Pancreatic cancer immune-checkpoint inhibitors tumor resistance MICROENVIRONMENT

INHIBITORS